ZA200904230B - Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline - Google Patents
Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolineInfo
- Publication number
- ZA200904230B ZA200904230B ZA200904230A ZA200904230A ZA200904230B ZA 200904230 B ZA200904230 B ZA 200904230B ZA 200904230 A ZA200904230 A ZA 200904230A ZA 200904230 A ZA200904230 A ZA 200904230A ZA 200904230 B ZA200904230 B ZA 200904230B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- pyrazol
- pyridin
- quinoline
- phenoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87126006P | 2006-12-21 | 2006-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200904230B true ZA200904230B (en) | 2010-04-28 |
Family
ID=39321475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200904230A ZA200904230B (en) | 2006-12-21 | 2009-06-17 | Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline |
Country Status (25)
Country | Link |
---|---|
US (1) | US8283471B2 (ru) |
EP (1) | EP2125786B1 (ru) |
JP (1) | JP5254602B2 (ru) |
KR (2) | KR20120043775A (ru) |
CN (1) | CN101611029B (ru) |
AR (1) | AR064417A1 (ru) |
AT (1) | ATE502028T1 (ru) |
AU (1) | AU2007343135B2 (ru) |
BR (1) | BRPI0720936A2 (ru) |
CA (1) | CA2673435C (ru) |
CY (1) | CY1111919T1 (ru) |
DE (1) | DE602007013294D1 (ru) |
DK (1) | DK2125786T3 (ru) |
ES (1) | ES2360014T3 (ru) |
HK (1) | HK1134670A1 (ru) |
IL (1) | IL199389A (ru) |
MX (1) | MX2009006528A (ru) |
NZ (1) | NZ577716A (ru) |
PL (1) | PL2125786T3 (ru) |
PT (1) | PT2125786E (ru) |
RU (1) | RU2430918C2 (ru) |
SI (1) | SI2125786T1 (ru) |
TW (1) | TWI359660B (ru) |
WO (1) | WO2008084299A1 (ru) |
ZA (1) | ZA200904230B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
TWI396689B (zh) * | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
US20120214842A1 (en) | 2011-02-18 | 2012-08-23 | Exonhit Therapeutics Sa | Methods for treating diseases of the retina |
EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | BENZOTHIOPHENE DERIVATIVE |
US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
KR102233916B1 (ko) * | 2019-05-28 | 2021-03-30 | 주식회사 엘지생활건강 | Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
ATE369330T1 (de) * | 2001-02-12 | 2007-08-15 | Wyeth Corp | O-desmethyl-venlafaxine succinat salz |
ES2258652T3 (es) * | 2001-11-29 | 2006-09-01 | Pfizer Products Inc. | Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos. |
UA75482C2 (en) * | 2001-12-12 | 2006-04-17 | Pfizer Prod Inc | Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer |
BRPI0413595B8 (pt) * | 2003-08-18 | 2021-05-25 | H Lundbeck As | sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto |
PL1841757T3 (pl) * | 2005-01-07 | 2010-10-29 | Pfizer Prod Inc | Heteroaromatyczne związki chinoliny i ich zastosowanie jako inhibitorów PDE10 |
WO2006078825A2 (en) | 2005-01-21 | 2006-07-27 | Cabot Corporation | Processes for forming nanoparticles |
BRPI0619962A2 (pt) * | 2005-12-16 | 2011-10-25 | Wyeth Corp | composições liofilizadas de um composto triazolopirimidina |
-
2007
- 2007-12-03 ES ES07858987T patent/ES2360014T3/es active Active
- 2007-12-03 AU AU2007343135A patent/AU2007343135B2/en not_active Ceased
- 2007-12-03 NZ NZ577716A patent/NZ577716A/xx not_active IP Right Cessation
- 2007-12-03 KR KR1020127009903A patent/KR20120043775A/ko not_active Application Discontinuation
- 2007-12-03 DK DK07858987.6T patent/DK2125786T3/da active
- 2007-12-03 CA CA2673435A patent/CA2673435C/en not_active Expired - Fee Related
- 2007-12-03 EP EP07858987A patent/EP2125786B1/en not_active Not-in-force
- 2007-12-03 BR BRPI0720936-3A patent/BRPI0720936A2/pt not_active IP Right Cessation
- 2007-12-03 DE DE602007013294T patent/DE602007013294D1/de active Active
- 2007-12-03 AT AT07858987T patent/ATE502028T1/de active
- 2007-12-03 SI SI200730561T patent/SI2125786T1/sl unknown
- 2007-12-03 WO PCT/IB2007/003819 patent/WO2008084299A1/en active Application Filing
- 2007-12-03 CN CN200780051566.5A patent/CN101611029B/zh not_active Expired - Fee Related
- 2007-12-03 US US12/515,612 patent/US8283471B2/en not_active Expired - Fee Related
- 2007-12-03 PL PL07858987T patent/PL2125786T3/pl unknown
- 2007-12-03 PT PT07858987T patent/PT2125786E/pt unknown
- 2007-12-03 KR KR1020097015193A patent/KR20090092338A/ko not_active Application Discontinuation
- 2007-12-03 RU RU2009123347/04A patent/RU2430918C2/ru not_active IP Right Cessation
- 2007-12-03 MX MX2009006528A patent/MX2009006528A/es active IP Right Grant
- 2007-12-18 AR ARP070105692A patent/AR064417A1/es not_active Application Discontinuation
- 2007-12-19 JP JP2007327323A patent/JP5254602B2/ja not_active Expired - Fee Related
- 2007-12-20 TW TW096148920A patent/TWI359660B/zh not_active IP Right Cessation
-
2009
- 2009-06-16 IL IL199389A patent/IL199389A/en active IP Right Review Request
- 2009-06-17 ZA ZA200904230A patent/ZA200904230B/xx unknown
-
2010
- 2010-02-10 HK HK10101480.3A patent/HK1134670A1/xx not_active IP Right Cessation
-
2011
- 2011-05-17 CY CY20111100481T patent/CY1111919T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
RU2430918C2 (ru) | 2011-10-10 |
TW200833337A (en) | 2008-08-16 |
TWI359660B (en) | 2012-03-11 |
KR20120043775A (ko) | 2012-05-04 |
JP2008208114A (ja) | 2008-09-11 |
JP5254602B2 (ja) | 2013-08-07 |
CA2673435A1 (en) | 2008-07-17 |
EP2125786A1 (en) | 2009-12-02 |
DK2125786T3 (da) | 2011-05-09 |
ES2360014T3 (es) | 2011-05-31 |
PL2125786T3 (pl) | 2011-07-29 |
WO2008084299A1 (en) | 2008-07-17 |
US8283471B2 (en) | 2012-10-09 |
BRPI0720936A2 (pt) | 2014-03-11 |
CY1111919T1 (el) | 2015-11-04 |
DE602007013294D1 (de) | 2011-04-28 |
KR20090092338A (ko) | 2009-08-31 |
NZ577716A (en) | 2012-10-26 |
CN101611029A (zh) | 2009-12-23 |
ATE502028T1 (de) | 2011-04-15 |
PT2125786E (pt) | 2011-04-21 |
CA2673435C (en) | 2012-10-09 |
HK1134670A1 (en) | 2010-05-07 |
US20100063089A1 (en) | 2010-03-11 |
AU2007343135B2 (en) | 2013-03-21 |
AU2007343135A1 (en) | 2008-07-17 |
SI2125786T1 (sl) | 2011-05-31 |
EP2125786B1 (en) | 2011-03-16 |
CN101611029B (zh) | 2014-09-10 |
IL199389A (en) | 2014-01-30 |
MX2009006528A (es) | 2009-06-26 |
AR064417A1 (es) | 2009-04-01 |
RU2009123347A (ru) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201101891B (en) | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide | |
HK1184147A1 (en) | Crystalline(r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h- indazol-3-yl)vinyl)-1h-pyrazol-1-yl) ethanol and its use as fgfr inhibitor ((r)-(e)-2-(4-(2-(5-(1-(35--4-))-1h--3-) )-1h--1-) fgfr | |
HK1203959A1 (en) | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2- | |
ZA200709715B (en) | Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate | |
IL206470A (en) | 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It | |
EP2038272B8 (en) | Pyridinonyl pdk1 inhibitors | |
IL196876A0 (en) | 2-(heterocyclylbenzyl)pyridazinone derivatives | |
EP1989187A4 (en) | 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE | |
SI2503993T1 (sl) | Hidrokloridna sol 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oksi) etil)morfolina | |
EP1954683A4 (en) | 2- (PHENYL OR HETEROCYCLIC) -1H-PHENANTRHO (9,10-D) IMIDAZOLES AS INHIBITORS OF MPGES-1 | |
ZA200904230B (en) | Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline | |
EP1828143A4 (en) | 1H-PHENANTHRO [9,10-D] IMIDAZOLES SUBSTITUTED INTO 2 BY PHENYL OR HETEROCYCLE AS INHIBITORS OF MPGES-1 | |
SI2531177T1 (sl) | 4-(2-((5-metil-1(2-naftalenil)-1h-pirazol-3-il)oksi)etil)morpholin hidroklorid polimorfi in solvati | |
HK1158627A1 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h- pyrrole derivatives as acid secretion inhibitors | |
IL197369A0 (en) | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)carbamoyl} | |
EP2118093A4 (en) | SUBSTITUTED QUINOLINES [1,2,3] TRIAZOLYL AND COUMARINS AS LEUCOTRIENE BIOSYNTHESIS INHIBITORS | |
IL194549A0 (en) | 2-(pyridin-2-yl)-pyrimidines for use as fungicides | |
PL2137160T3 (pl) | 4-(4-trifluorometylo-3-tiobenzoilo)pirazole i ich zastosowanie jako herbicydów | |
IL220851A (en) | Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process | |
ZA201008283B (en) | Fumarate salt of 4-(3-chloro-2-fluoroanilino) -7-methoxy-6-{[1-(n-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline | |
ATE514685T1 (de) | Herbizid wirksame 4- (3-aminobenzoyl) -5- cyclopropylisoxazole | |
ZA201003031B (en) | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465 | |
IL200959A0 (en) | Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine | |
EP2017252A4 (en) | 4- (4-alkylcyclohexyl) benzaldehyde | |
HK1223606A1 (zh) | 三氟甲基 苯甲基 -甲氧基丁醯胺的多晶型物 |